… Myeloma Working Group's clinical practice recommendations for the treatment of relapsed
and refractory multiple myeloma… the treatment of patients with relapsed and refractory disease …

… The therapeutic strategy for relapsed and refractory multiple myeloma (RRMM) integrates a
holistic approach regarding patient, disease, and drug-related factors. Patient-related factors …

… critical unmet need for treatments for patients with late-stage, highly refractory disease. In …
treatment options for heavily pretreated patients with relapsed and refractory multiple myeloma, …

… Criteria for relapsed/refractory multiple myeloma (RRMM) … (PD), progressive disease on
treatment or after at least minimal … treatment, the absence of at least MR on a given therapy (…

… (RRMM) have been treated with drug combinations including a proteasome inhibitor (PI) and…
of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. …

… be several remissions and relapses until resistance develops to available therapies. Myeloma
treatment options have increased and, while advances in primary therapy have improved …

… treatment options, the evolving treatment landscape has created challenges. Patients with
relapsed refractory multiple myeloma (… There is no simple treatment algorithm, with therapeutic …

… Addressing relapse can be complex and challenging as there are both therapy- and patient-…
In this broad scoping review of available therapies in relapsed/refractory multiple myeloma (…

… multiple myeloma refractory to all 3 of these agents has emerged. This population, for whom
a clear treatment … The current approaches to the treatment of triple-class refractory disease …

… The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new … access and availability of new treatment options in the salvage setting. In the US, where …